However, in hepatocellular carcinoma cells, EZH2 enhances H3K27me3 at the promoters of CD274, which encodes PD-L1, and interferon regulatory factor 1 (IRF1), leading to an inverse correlation by inhibiting PD-L1 expression (32). Here, EZH2 is linked to hepatocellular carcinoma.